Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

SELL
$45.8 - $85.4 $10.4 Million - $19.4 Million
-227,600 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$62.2 - $84.4 $14.2 Million - $19.2 Million
227,600 New
227,600 $16.5 Million
Q4 2019

Feb 14, 2020

SELL
$36.08 - $45.83 $30.1 Million - $38.2 Million
-834,313 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$42.5 - $63.11 $32.1 Million - $47.6 Million
754,706 Added 948.04%
834,313 $35.7 Million
Q2 2019

Aug 14, 2019

BUY
$54.93 - $74.36 $4.37 Million - $5.92 Million
79,607 New
79,607 $5.06 Million
Q3 2018

Nov 14, 2018

SELL
$71.81 - $90.15 $4.85 Million - $6.09 Million
-67,605 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$48.54 - $85.31 $3.28 Million - $5.77 Million
67,605 New
67,605 $5.2 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $2.8B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.